Autoimmune diseases

New safety warnings for JAK inhibitors

The US Food and Drug Administration (FDA) is imposing new restrictions and warnings on JAK inhibitors in the treatment of rheumatic inflammatory disorders after a tofacitinib safety trial showed an increased risk of major adverse cardiovascular events, malignancy, thrombosis, and mortality. The measures will apply to tofacitinib, baricitinib, and upadacitinib, based on results from a ...

Already a member?

Login to keep reading.

© 2021 the limbic